Kazia Therapeutics Named Drug Discovery Company of Year
The oncology biotech earned the 2026 BioTech Breakthrough Awards honor for its next-generation cancer therapeutic approach.
Updated on Nov. 5, 2026 in Biotech
Kazia Therapeutics, an oncology-focused biotechnology company listed on NASDAQ under KZIA, was named Drug Discovery Company of the Year in the 2026 BioTech Breakthrough Awards. The recognition was announced in a press release dated November 5, 2026.
Why it matters
The award was based on evaluation by an independent panel of industry experts, and Kazia was recognized for its innovative approach to developing next-generation cancer therapeutics. The honor highlights ongoing interest in therapies aimed at tumors that evade the immune system or resist existing treatments.
The recognition comes from an independent panel of industry experts evaluating entries on innovation, performance, value and impact, with two preclinical assets (NDL2 and MSETC) in the pipeline. The source does not disclose the full field of competing entrants.
The players
Kazia Therapeutics Limited
An oncology-focused biotechnology company listed on NASDAQ under the ticker KZIA, developing targeted cancer therapies.
BioTech Breakthrough Awards
An industry awards program that recognizes biotechnology companies, with winners selected by an independent panel of industry experts.
The details
Kazia's lead asset is paxalisib, an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being studied in triple-negative breast cancer, HR+/HER2- breast cancer and MSS/pMMR colorectal cancer. The company also holds EVT801, a VEGFR-3 inhibitor it is exploring for partnering opportunities.
Timeline
2026: Kazia named Drug Discovery Company of the Year in the BioTech Breakthrough Awards.
November 5, 2026: Kazia announces the recognition in a press release datelined Sydney.
Pipeline Context
Paxalisib's U.S. FDA Fast Track and Orphan Drug designations for glioblastoma provide the regulatory backdrop for the company's broader oncology push. The award extends that attention to Kazia's preclinical NDL2 and MSETC programs.
For patients whose cancers no longer respond to available treatments, the company's pipeline represents a possible future option, though the drugs remain investigational. The award itself does not change access to any approved therapy.
The takeaway
Industry recognition such as this award signals investor and expert attention to novel mechanisms in cancer treatment, but investigational therapies still require clinical validation before reaching patients.
Further reading
For more on the research pipelines behind awards like this, explore Biotech coverage.
Source note: This article includes information reported by Vietnam Tribune.
